Jumpcan
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 6.2b | 7.6b | 9.0b | 9.7b | 10.0b | 10.9b | 11.7b |
| % growth | (11 %) | 24 % | 18 % | 7 % | 4 % | 8 % | 8 % |
| EBITDA | 1.8b | 2.3b | 2.9b | 3.6b | 3.6b | 3.9b | 4.3b |
| % EBITDA margin | 29 % | 30 % | 32 % | 37 % | 36 % | 36 % | 37 % |
| Profit | 1.3b | 1.7b | 2.2b | 2.8b | 3.0b | 3.4b | 3.8b |
| % profit margin | 21 % | 23 % | 24 % | 29 % | 30 % | 31 % | 32 % |
| EV / revenue | 2.9x | 3.3x | 2.8x | 3.0x | 2.7x | 2.5x | 2.3x |
| EV / EBITDA | 10.0x | 11.0x | 8.8x | 8.1x | 7.6x | 6.9x | 6.4x |
| R&D budget | 244m | 523m | 553m | 464m | - | - | - |
| R&D % of revenue | 4 % | 7 % | 6 % | 5 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
* | N/A | Post IPO Equity | |
| Total Funding | - | ||
Recent News about Jumpcan
EditJumpcan is a pharmaceutical company that provides a range of services including internet drug information and COVID-19 nucleic acid test agents. The company primarily serves healthcare providers and pharmacies, operating within the pharmaceutical and healthcare market. Jumpcan's business model revolves around offering specialized pharmaceutical products and services, generating revenue through the sale of these products and services to its clients. The company is known for its expertise in drug information services and its proactive approach to addressing public health needs, such as the COVID-19 pandemic.
Keywords: pharmaceutical, internet drug information, COVID-19, nucleic acid test, healthcare, pharmacies, drug services, public health, healthcare providers, pharmaceutical products.
